Aims: Hypomagnesemia (serum magnesium [Mg] <0.74 mmol/L [<1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D.
Methods: In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL).
Results: A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95% confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8% (95% CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment.
Conclusions: Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdiacomp.2019.06.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A clinical audit of hypomagnesaemia management at Scarborough General Hospital.
Future Healthc J
March 2025
Scarborough Hospital, Woodlands Dr, Scarborough, YO12 6QL, United Kingdom.
Background: Hypomagnesaemia is a common electrolyte disturbance that can lead to severe complications, including cardiac dysrhythmias and neuromuscular instability. Despite established guidelines by the York and Scarborough Teaching Hospitals NHS Foundation Trust, there is concern that these protocols are not consistently followed, potentially compromising patient outcomes. Objective: This audit aimed to evaluate the management of hypomagnesaemia at Scarborough General Hospital, focusing on adherence to trust guidelines and identifying areas for improvement in clinical practice.
View Article and Find Full Text PDFHypocalcemia as an Independent Cause of Esophageal Dysphagia: A Case Report.
Cureus
September 2024
Department of Medicine, Royal Preston Hospital, Preston, GBR.
Article Synopsis
- - Dysphagia, or difficulty swallowing, can be linked to low calcium levels (hypocalcemia), which impair the function of muscles involved in swallowing; certain diuretics may worsen this condition by causing additional loss of calcium and magnesium.
- - An 82-year-old male experienced sudden dysphagia and was found to have severe hypocalcemia and hypomagnesemia, likely exacerbated by his use of furosemide, a diuretic.
- - After treatment with intravenous calcium and magnesium over two days, the patient’s electrolyte levels normalized and he significantly improved, regaining the ability to swallow normally, confirming that his symptoms were primarily due to low calcium levels.
Atypical fundoscopic manifestation with good visual prognosis in familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
Ophthalmic Genet
December 2024
Department of Ophthalmology, University Hospital Virgen Macarena, Seville, Spain.
Article Synopsis
- Pathogenic variants in the CLDN19 gene lead to Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC), which also includes eye-related issues.
- A 25-year-old woman with FHHNC showed significant renal involvement and various eye problems, including high myopia and atrophic retinal plaques, alongside genetic testing that revealed a specific mutation in the CLDN19 gene.
- The study suggests that FHHNC is linked to diverse ocular changes, and the described retinal issues in this patient may indicate a more favorable visual outlook than previously documented, highlighting the need for more research in this area.
Unveiling the Link: Hypocalcemia-Induced Unstable Sustained Ventricular Tachycardia in Nonischemic Cardiomyopathy.
Cardiol Res
August 2024
Department of Cardiology, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Article Synopsis
- - A 63-year-old woman arrived at an emergency room experiencing dizziness, palpitations, and low blood pressure; she was diagnosed with ventricular tachycardia and electrolyte imbalances (low magnesium and calcium levels).
- - Despite treatment with IV amiodarone and magnesium, her tachycardia only resolved after her serum calcium levels were corrected.
- - The patient had a history of left ventricular dysfunction discovered 19 years earlier but was unaware and not on any medication; the case suggests a possible link between her underlying heart condition and the rare occurrence of hypocalcemia-related ventricular tachycardia.
Gitelman syndrome with primary hyperparathyroidism: A case report.
Medicine (Baltimore)
August 2024
Division of Nephrology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Gitelman syndrome (GS) is a rare genetic disorder causing salt loss in the kidneys, but a patient with GS was newly diagnosed with hypercalcemia and primary hyperparathyroidism (PHPT).
- The patient had a long history of low potassium and magnesium levels, and lab tests confirmed GS alongside PHPT, highlighted by parathyroid hyperplasia.
- Treatment improved her potassium levels and joint pain, but managing her magnesium levels remained difficult due to increased urinary excretion caused by PHPT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!